Blood pressure control with active ultrafiltration measures and without antihypertensives is essential for survival in hemodiafiltration and hemodialysis programs for patients with CKD. A prospective observational study.

Between 60% of hemodialysis patients have hypervolemia. The present study hypothesizes that there is more notable survival in CKD patients whose hypertension can be controlled without antihypertensives and with ongoing dry weight reduction with the point-of-care dry weight (POC-DW) technique.
Blood pressure control with active ultrafiltration measures and without antihypertensives is essential for survival in hemodiafiltration and hemodialysis programs for patients with CKD. A prospective observational study.
Like

Share this post

Choose a social network to share with, or copy the URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

Explore the Research

BioMed Central
BioMed Central BioMed Central

Blood pressure control with active ultrafiltration measures and without antihypertensives is essential for survival in hemodiafiltration and hemodialysis programs for patients with CKD: a prospective observational study - BMC Nephrology

Background High blood pressure is a prevalent condition in patients with chronic kidney disease on hemodialysis. Adequate control of high blood pressure is essential to reducing deaths in this group. The present study aimed to observe mortality prospectively in a group of patients in hemodialysis and hemodiafiltration programs in whom the use of antihypertensives was optimized with the point-of-care dry weight (POC-DW) technique. Methods The present observational, prospective study was carried out at the Pafram hemodiafiltration unit in Morona Santiago, Ecuador, and the hemodialysis unit of the Fundación Renal del Ecuador in Guayaquil, Ecuador, from August 2019 to December 2023. Patients who were receiving hemodiafiltration were included. Weight was optimized with POC-DW for eight weeks. In Group 1, patients whose use of antihypertensive drugs was not required to control systolic blood pressure with a value less than 150 mmHg predialysis, less than 130 mmHg postdialysis, and a peridialytic blood pressure (defined as post-HD minus pre-HD SBP) between 0 and − 20 mmHg were analyzed. In Group 2, patients who required antihypertensive drugs for not meeting the aims of systolic blood pressure were included. The variables included clinical, demographic, mortality, description of the treatment, and routine laboratory tests in dialysis programs. The sample was nonprobabilistic. Survival analysis was performed for the study groups. The log-rank test (Mantel-Cox) was used for survival comparisons. Results The study included 106 patients. Optimal blood pressure control without antihypertensive treatment was achieved in 52 patients (49.1%) (Group 1). In 54 patients (50.9%), antihypertensive agents were required (Group 2). There was more significant mortality in the group that received antihypertensives: 11 patients in group 1 (21.2%) versus 25 patients in group 2 (46.3%) (P = 0.005). Survival was more significant in group 1, with an HR of 2.2163 (1.125–4.158) (P = 0.0243). Conclusion In hemodiafiltration and hemodialysis programs, blood pressure control with active ultrafiltration measures and without using antihypertensives is essential for survival in patients with CKD.

The main finding confirms the hypothesis of the study that there is more remarkable survival in the group of patients with CKD whose hypertension can be controlled without antihypertensive treatment and with the use of constant dry weight reduction measures to optimize ultrafiltration. The factors associated with the lack of control of arterial hypertension were a history of vascular amputation, a history of being an ex-smoker, being a carrier of type 2 diabetes mellitus, having a serum ferritin level greater than 26.75%, being male, and being treated with hemodialysis. The associated protective factors were having a diagnosis of glomerulonephritis as an etiology of chronic kidney disease, a history of never smoking, a serum ALB concentration greater than 4.214 g/dl, effective blood flow greater than 423.5 ml/min, and interdialytic weight gain >4.925%, hemodiafiltration as treatment, urea levels less than 103.78 mg/dl, and fasting glucose levels less than 109.2 mg/dl. According to the time-adjusted model, only four factors were associated: age, transferrin saturation, serum albumin levels, and history of vascular amputation.

In the stratified analysis, differences in survival were demonstrated by the percentiles of blood pressure taken in the last month of survival or censoring. With blood pressures ranging from 141 mmHg to 122 mmHg, there is a proportional risk of death associated with the intake of antihypertensive agents. The same occurs when the blood pressure is less than 105 mmHg. These relationships could not be established with pressures greater than 141 mmHg.

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Follow the Topic

Nephrology
Life Sciences > Health Sciences > Clinical Medicine > Nephrology
Haemodialysis
Life Sciences > Health Sciences > Clinical Medicine > Therapeutics > Renal replacement therapy > Haemodialysis
Mortality and Longevity
Humanities and Social Sciences > Society > Population and Demography > Mortality and Longevity
Risk Factors
Life Sciences > Health Sciences > Public Health > Health Promotion and Disease Prevention > Risk Factors
  • BMC Nephrology BMC Nephrology

    This is an open access journal publishing original peer-reviewed research articles in all aspects of the prevention, diagnosis and management of kidney and associated disorders, as well as related molecular genetics, pathophysiology, and epidemiology.

Your space to connect: The Cancer in understudied populations Hub

A new Communities’ space to connect, collaborate, and explore research on Cancers, Race and Ethnicity Studies and Mortality and Longevity!

Continue reading announcement

Related Collections

With Collections, you can get published faster and increase your visibility.

Risk stratification through AI application in kidney care

The increasing global burden of chronic kidney disease (CKD) necessitates an ongoing exploration of innovative strategies to enhance patient management and optimise healthcare delivery. Artificial Intelligence (AI) offers unprecedented opportunities for risk stratification in kidney care, harnessing vast datasets to inform clinical decision-making, improve patient outcomes, and drive efficiencies in healthcare systems.

AI-based CKD progression prediction models leverage machine learning algorithms to analyse patient data, enabling healthcare professionals to identify individuals at heightened risk of disease progression. These tools have been validated in various clinical settings and demonstrate considerable potential in personalising patient care.

Machine learning risk scoring for dialysis initiation has emerged as a vital resource, improving decision-making processes by facilitating timely interventions. Predictive analytics for transplant eligibility ensure that patients receive the most suitable and timely interventions based on their unique health profiles. This algorithmic stratification of renal patient cohorts allows for a more nuanced understanding of patient needs, moving us beyond a one-size-fits-all approach to a model that emphasises individualised care.

The potential of AI in risk stratification encompasses the broad spectrum of healthcare delivery, influencing policy formulation, resource allocation, and patient education. By continuing to expand our collective understanding in this area, we can foster an environment where AI-driven innovations are systematically integrated into kidney care protocols.

Topics of interest include but are not limited to:

  • AI-based CKD progression prediction
  • Machine learning risk scoring for dialysis initiation
  • Predictive analytics for transplant eligibility
  • Algorithmic stratification of renal patient cohorts
  • Personalised nephrology risk models
  • Integration of social determinants in risk assessment
  • Impact of AI on patient engagement and outcomes
  • Interoperability challenges and solutions in kidney care

We welcome submissions employing AI and Machine Learning approaches, as well prediction models that use regression or machine learning methods. We recommend adhering to TRIPOD guidelines for reporting clinical prediction models that use regression or machine learning methods.

We encourage authors to share accompanying data. According to our policies, submission of a manuscript to a BMC journal implies that materials described in the manuscript, including all relevant raw data, will be freely available to any scientist wishing to use them for non-commercial purposes, without breaching participant confidentiality. We require data deposition for some data types. Further information can be found in our policies.

This Collection supports and amplifies research related to SDG 3: Good Health and Well-being.

All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.

Publishing Model: Open Access

Deadline: Mar 19, 2027

Mental health integration in nephrology

The intersection of mental health and nephrology is gaining increasing recognition as a critical component of integrated patient care. Chronic kidney disease (CKD), along with treatments such as dialysis and kidney transplantation, is frequently associated with significant psychological distress, leading to poorer health outcomes. This Collection aims to explore the integration of mental health support within nephrology practices, addressing how psychological factors influence disease management and patient quality of life.

Recent advances in this field include the implementation of routine depression screening in dialysis settings and the development of integrated behavioral health models within nephrology clinics. These strategies have shown promise in addressing the psychological needs of patients and their family caregivers, fostering better adherence to treatment regimens, and ultimately improving physical and mental well-being among this population.

We welcome submissions including original research, reviews, and implementation studies. Topics of interest include, but are not limited to:

  • Psychological support in CKD
  • Depression screening in dialysis and transplant patients
  • Integrated behavioral health in nephrology care
  • Cognitive and behavioral interventions in CKD management
  • Digital mental health interventions in nephrology
  • Dyadic and family-based interventions in CKD management

This Collection supports and amplifies research related to SDG 3: Good Health and Well-being

All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.

Publishing Model: Open Access

Deadline: Jan 30, 2027